2024-04-23 10:00:00 ET
Summary
- Novartis reported strong first quarter results with an EPS beat and revenue beat.
- The company's core growth products, including Entresto, Cosentyx, Kesimpta, Kisqali and Leqvio, drove the strong first-quarter performance.
- Novartis increased its full-year revenue and operating income growth guidance.
- Healthy balance sheet and cash flow generation leave room for continued business development activity on top of dividends and share repurchases.
- Entresto going generic remains the key medium-term risk.
Novartis ( NVS ) is off to a strong start in 2024 with a $0.12 EPS beat and a $330 million revenue beat. The year-over-year comparisons by Seeking Alpha note an 8.6% decline in revenues compared to the same quarter last year, but this comparison includes the divested Sandoz division and the existing business that excludes Sandoz generated a 10% Y/Y increase in total revenues in the first quarter of the year along with a 22% Y/Y increase in operating income thanks to the exclusion of the lower margin Sandoz business....
Read the full article on Seeking Alpha
For further details see:
Novartis: Strong Start To The Year With Beat-And-Raise First Quarter Results